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Healthcare-associated infections are a concern for health service providers, exacerbated by poor delivery 
of antimicrobials to target sites within the skin. The dermal route is attractive for local and systemic delivery 
of drugs however; permeation, penetration and access to deeper skin layers are restricted due to the barrier 
function of the stratum corneum. Solid lipid nanoparticles present several benefits for topical delivery for 
therapeutic applications, especially via the follicular route. Hair follicles, surrounded by a close network of 
blood capillaries and dendritic cells, are an important target for delivery of antimicrobials and present a 
unique microbial nidus for endogenous infections in situations where the barrier is disrupted, such as after 
surgery, for example. Triclosan, a broad-spectrum antimicrobial agent, was encapsulated into nanoparticles 
using glyceryl behenate and glyceryl palmitostearate solid lipids, and incorporating Transcutol P, a known 
permeation enhancer at different ratios. Optimised formulation were stable over 90 days and in vitro 
permeation studies using full thickness porcine ear skin showed that the lipid-based nanoparticles enhanced 
delivery of triclosan into the skin and could direct the agent towards hair follicles, indicating their potential 
as a carrier system for antiseptic dermal delivery. 
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Healthcare-associated infections (HAIs) are a major concern inflicting significant financial 
burdens and time constraints on healthcare systems due to increased morbidity and mortality rates, 
prolonged hospital occupancy and intensified treatment regimes, including repeated surgeries 
(Vilela et al. 2007). Surgical site infections (SSIs) are a major source of prolonged illness, and a 
significant cause of death in surgical patients. SSIs occur due to microbial contamination and these 
microorganisms may originate from either internal or external sources, which includes the patient’s 
own skin, mucous membranes or any contaminated item in the sterile surgical field, including 
surgical team members, instruments, air, or materials (De Lissovoy et al. 2009). Many aspects of 
current research to prevent SSIs involve more effective use of antiseptics in order to counteract the 
world-wide concern of rising antibiotic resistance and the lack of new antibiotic groups entering 
pharmaceutical development (Leaper et al. 2013). The pilosebaceous units, which are composed 
of sweat glands (eccrine and apocrine), sebaceous glands and hair follicles, present their own 
unique nidus and are the most favourable place for microorganism growth due the moist and lipid-
rich environment (Grice and Segre 2011). However, due to the natural properties of the skin as a 
protection barrier, there is limited potential for delivery of effective amounts of antimicrobial 
agents into the skin and this has long been a driver for new strategies to improve penetration of 
drugs to target microorganisms residing in different areas within the skin (Cevc 1997). Different 
carrier systems have been developed in an attempt to facilitate the transport of drugs through the 
skin, enabling drug retention and, in some cases, allowing a controlled release (Kim et al. 2002, 
Sabu et al. 2018). Amongst these systems, solid lipid nanoparticles (SLNs) are expected to form a 
depot in the hair follicles, providing targeted controlled drug delivery (Aljuffali et al. 2013). 
SLNs were developed at the beginning of 1990s as an alternative carrier system to emulsions and 
liposomes by replacing the liquid lipid (oil) of an emulsion by a solid lipid or a blend of solid 
lipids, i.e. a lipid which is solid at both room and body temperature. SLNs can accommodate both 
lipophilic and hydrophilic drugs with negligible skin irritation and have improved physical 
stability and lower cost of production compared to liposomes (Müller, Mäder, Gohla, et al. 2000). 
Moreover, SLNs have distinct occlusive properties due to the formation of an intact film on the 
skin surface, which can increase hydration of the stratum corneum (SC) and disrupt packing of 
corneocytes, thereby facilitating drug penetration into deeper layers of the skin (Jenning and Gohla 
2001, Khezri et al. 2018). In addition to the occlusive effect, enhanced drug penetration can also 
be related to nanometer dimensions of SLNs because the higher surface area facilitates contact of 
the encapsulated drug with the SC and may favour accumulation for several hours, which allows 
for sustained drug release (Schäfer-Korting et al., 2007).  
TSN (2,4,4-trichloro-hydroxydiphenylether) is a non-cationic, synthetic, broad-spectrum 
antimicrobial agent used in many soaps, creams, and solutions in concentrations of up to 2% w/w 
for disinfection of the hands and wounds and for disinfection of the skin before surgery, and in 
biodegradable sutures. It is used also in oral hygiene products and in preparations for acne and 
consumer products, such as antibacterial soaps, toothpastes, cosmetics, clothing, kitchenware and 
toys. Reported minimum inhibitory concentrations (MIC) of TSN for Staphylococcus aureus range 
between 0.025 g/ml to 1 g/ml (Suller and Russell 2000).  Polymeric nanoparticles of triclosan 
(TSN) have been previously evaluated for topical delivery (Domínguez-Delgado et al. 2011, Fagui 
et al. 2013) with synthesis involving the use of organic solvents, which may cause toxicological 
issues and irritation. Triclosan has a logP of 4.8 and a pKa of 8.1 (Carter et al. 2014) and so has 
limited local availability within the skin and the hair follicles.  
The aim of our study is to develop SLNs of TSN using a solvent-free method involving hot high 
shear homogenisation (HSH) followed by probe ultrasonication for delivery to the hair follicles. 
Glyceryl behenate (GB) and glyceryl palmitostearate (GP) were selected as solid lipids. These 
lipids are used as thickening agents for topical emulsions and ointments and have been used for 
SLN formulations previously (Quintanar-Guerrero et al. 2005). Tween® 80 (T80) and Transcutol® 
P (TP) were used as surfactant and cosurfactant respectively. TP has been previously reported to 
enhance skin penetration for a variety of drugs when used in creams, lotions, microemulsions and 
aqueous gels (Rowe et al. 2012). Hence the use of TP in SLN formulations is a novel approach to 
study the increase in skin penetration of TSN. 
SLNs were characterised for various physicochemical properties such as particle size, zeta 
potential, morphology, physical and thermal stability and crystallinity and the formulations 
evaluated as a topical delivery system using frozen, excised, full thickness porcine ear skin.  
 
2. Materials and methods 
 2.1 Materials 
Triclosan was obtained from Vivimed (Mumbai, India). Glyceryl behenate, glyceryl 
palmitostearate and Transcutol® P were donated by Gattefossé (UK). Tween® 80 and sodium lauryl 
sulphate were purchased from Sigma Aldrich (UK). All other solvents and reagents were of 
analytical grade.  
2.2 Chromatographic detection of triclosan 
Chromatographic analysis of TSN was performed on a Shimadzu HPLC equipped with a SPD-20 
AV Prominence UV/Visible detector set at 280 nm, an LC-20AT pump, and SIL-20A Prominence 
auto sampler. Separation of TSN was performed using a Kinetex® pentaflurophenyl 5 m column 
(250 x 4.6 mm) (Phenomenex, UK) maintained at 30°C and TSN was eluted with a mobile phase 
consisting of acetonitrile and water (60:40 v/v) at a flow rate of 1 ml/min. Injection volume was 5 
L with retention time of 7.34 min. Standard solutions of TSN were prepared at concentration of 
1, 5, 10, 20, 30, 40 and 50 g/ml and these standards were used to determine the linearity (R2  = 
0.999) and the limit of detection (0.60 g/ml) during HPLC method validation. 
2.3 Preparation of solid lipid nanoparticles 
SLNs were prepared by HSH followed by probe ultrasonication (Kamble et al. 2012, Patel et al. 
2012, Nerella et al. 2014, Kaur et al. 2016). Briefly, the lipid phase was prepared by heating lipids 
(GB and GP) to 5 ºC above their melting points and TSN (equivalent to 10 mg/g of formulation) 
was added to the lipids while the aqueous phase was prepared by heating Smix (T80 and TP) and 
water to same temperature. The hot lipid phase was added slowly to the hot aqueous phase under 
HSH (Silverson, UK). This hot primary emulsion was then subjected to probe ultrasonication 
(Sonics and Materials Inc., USA) for 10 min at 70 % frequency amplitude. The resultant dispersion 
was cooled to room temperature to solidify the lipids, forming an SLN aqueous dispersion (Mu 
and Holm 2018). The impact of homogenisation variables on the SLNs was investigated (i.e. 
homogenisation speed was varied from 4000 rpm to 10,000 rpm and the duration of 
homogenization ranged from 5 min to 15 min). In addition, the effect of various formulation 
parameters, such as ratio of surfactant to cosurfactant and lipid to drug ratio, on mean particle size 
and drug entrapment efficiency were studied.  For solid-state characterisation only, SLNs were 
freeze dried in glass vials under vacuum at atmospheric pressure for 24 h to obtain a powder and 
samples were stored at 4°C until tested (Christ LD 2-4 Plus, UK).  
2.4 Physicochemical characterisation  
2.4.1 Particle size analysis 
The particle size and polydispersity index (PDI) of nanoparticles was measured using nanoparticle 
tracking analysis (NTA, Nanosight LM10, UK). Each sample was suitably diluted with ultrapure 
water to maintain the concentration of sample between 40 – 65 particles/frame and. samples were 
measured in triplicate to obtain mean particle size and PDI was calculated. 
2.4.2 Zeta potential measurement  
In order to determine the surface charge on nanoparticles, the zeta potential (ZP) was measured 
using a Zetasizer Nano Z (Malvern Instruments Ltd, UK). Each sample was suitably diluted with 
filtered, distilled water and placed in a disposable zeta cell. Zeta limit ranged from -200 to +200 
mV.  
 
2.4.3 Determination of drug entrapment efficiency 
The percent drug entrapment efficiency (% DEE), which corresponds to the percentage of TSN 
encapsulated within the nanoparticles, was determined by measuring the concentration of free TSN 
as well as the total concentration of TSN in the dispersion medium. To measure total TSN 
concentration freeze-dried SLNs were dissolved in a chloroform and methanol (1:1 v/v) mixture 
and sonicated to extract drug from the lipid, while free and unentrapped drug was measured by 
dissolving the particles in a suitable solvent. Both samples were analysed using the validated 
HPLC method (section 2.2) and % DEE was calculated. 
2.4.4 Differential scanning calorimetry 
The thermal behavior of drug and SLNs was analysed by differential scanning calorimetry (DSC) 
using a Mettler Toledo DSC1 (STARe system, UK), calibrated using an indium standard. Samples 
(8-10 mg) of pure TSN, GB and GP lipids, equivalent ratio of physical mixtures of drug and lipids 
(PM) and lyophilised TSN-loaded SLNs were analysed in vented 40 µl aluminum pans. The 
thermograms were recorded over a temperature range of 25-160C at a heating rate of 10C/min 
under a continuous nitrogen gas purge, maintained at a flow rate of 50 ml/min (Kotikalapudi et al. 
2012).  
 
2.4.5 Powder X-ray diffraction analysis 
 
The effect of the encapsulation process on the crystallinity of the TSN was investigated using X-
ray powder diffractometer (XRD) using freeze-dried samples. Powder X-ray diffractogram of the 
TSN, pure lipid GB and GP, physical mixture of drug and lipids, TSN loaded lipid nanoparticles 
were analysed using a Bruker diffractometer (Bruker D2 Phase, UK). Samples were placed in a 
stainless steel holder and the surface powder was levelled manually. Each sample was scanned 
between 5 and 40 of 2θ with step size of 0.019 and a step time of 32.5 seconds.  
 
2.4.6 Nanoparticle morphology 
The morphology of SLNs was confirmed using transmission electron microscopy (TEM) using a 
JEOL 3010, which was operated at 300 kV. The SLN suspension was diluted with water and a 
drop was placed on a 20-mesh carbon coated copper grid (Agar Scientific, UK). Excess sample 
was removed with filter paper and to achieve effective imaging contrast, the samples were 
negatively stained with 1% (w/w) phosphotungstic acid for 1 min and air dried at room temperature 
(Kupetz and Bunjes 2014) . 
2.4.7 Stability study 
Selected SLN formulations stored at room temperature (~ 20C) and in a humidity chamber 
(40C/75% RH) over a period of three months. The average particle size, PDI and ZP were 
measured at day 30, day 60 and day 90. The samples were studied in triplicate and results were 
expressed as mean ± SD. 
2.4.8 Skin permeation study 
2.4.8.1 In vitro skin permeation study 
In vitro permeation studies (n = 6 for each formulation and control) were carried out over a period 
of 24 h using vertical Franz diffusion cells with a diffusion area of 3.8 cm2 and a receiver 
compartment volume of 30 ml. Porcine skin is reported to be the most appropriate animal model 
due to the numerous anatomical, histological and physiological similarities with human skin (Dick 
and Scott 1992, Godin and Touitou 2007, Flaten et al. 2015). Frozen excised full thickness porcine 
ear skin was used in this study was thawed for 30 min and then hydrated by immersing in phosphate 
buffer saline (PBS) pH 7.4 solution for 60 min prior to the start of each experiment. The skin was 
then cut into appropriate sections and mounted on the Franz diffusion cell, with SC facing the 
donor compartment (where the formulation was applied) and the dermis facing the receiver 
compartment. The receiver compartment contained PBS solution (pH 7.4) containing 1 % w/w 
SLS (150mM), in order to ensure skin conditions were maintained throughout the study and water 
was circulated at 37C to maintain a skin surface temperature at 32C, with stirring speed of 200 
rpm for 24 h. The skin was equilibrated for 30 min before loading with SLN formulations 
(equivalent to 10 mg/g TSN concentration in an aqueous dispersion) or saturated solution of TSN 
(10mg/g) in 1% w/w SLS as control to each donor compartment and covered with Parafilm to 
prevent evaporation. Samples (500 l) were withdrawn at regular intervals from receiver 
compartment (normally 2, 4, 6, 8, 10, 12 and 24 h) and replaced by an equal volume of fresh 
receiver solution to maintain sink conditions. The amount of TSN permeated through skin over 24 
h was analysed by HPLC. 
2.4.8.2 Quantification of triclosan from skin using differential stripping techniques 
After permeation studies, the skin was removed from diffusion cells and surface of the skin was 
thoroughly washed with distilled water to remove any excess formulation from the surface and 
allowed to dry at ambient temperature. A differential stripping technique was used to quantify 
amount of TSN in porcine skin by combining tape stripping and cyanoacrylate biopsy (Teichmann 
et al. 2005, Wosika and Cal 2010). The skin was tape-stripped 15 times using an adhesive surgical 
tape (3M Transpore, UK). Tape 1 was analysed individually as this might contain unabsorbed 
materials on the skin surface, whereas tapes 2-5 and 6-15 were analyse together to determine the 
amount of TSN in SC. Following tape stripping, a drop of cyanoacrylate glue was placed on the 
skin and covered with adhesive tape applied under slight pressure. After 10 min, the cyanoacrylate 
polymerised and the strip was removed, entrapping the casts of hair follicles. Two successive 
cyanoacrylate applications were applied to each skin sample and analysed individually. 
After stripping, the skin was weighed accurately and cut into fine pieces. All skin samples were 
placed into vials containing 10 ml of methanol and sonicated for 30 min. After sonication 
(Transonic, UK), the samples were centrifuged for 20 min at 400 rpm (Eppendorf centrifuge 5702, 
UK). The supernatant was collected after centrifugation and the amount of TSN retained in 
remaining skin tissue was determined using HPLC. 
2.4.9 Statistical analysis  
All particle size, zeta potential and in vitro permeation measurements were performed in triplicate 
and values were analysed using one way ANOVA (GraphPad Prism 6) with differences considered 
to be statistically significant when p< 0.05.  
 
3. Results and discussion 
SLNs were formulated and optimised using GB and GP as solid lipids in different concentrations 
of 3, 5, 7.5 and 10 % (w/w). These lipid carrier systems were stabilised by T80 and TP in different 
ratios such as 1:1, 2:1, 3:1 and 4:1 respectively. Studying the effect of process and formulation 
variables on mean particle size and drug entrapment efficiency enabled selection of SLN 
formulations for further study. 
 
3.1 Optimisation of process variables 
To optimise homogenisation speed and time, GB-SLNs (GB5-2) and GP-SLNs (GP5-2) were 
prepared and the effect of different homogenisation speed and time on the mean particle size was 
determined. It was observed that by increasing homogenising speed from 4000 rpm to 10,000 rpm 
mean particle size decreased from 520 ± 0.24 nm to 193 ± 0.51 nm for GB-SLNs, while in case of 
GP-SLNs mean particle size decreased from 584 ± 0.47 nm to 173 ± 0.36 nm. 
The effect of homogenisation time on mean particle size was studied by homogenising SLN 
formulations for 5, 10 and 15 min. As the duration of homogenisation was extended from 5 to 10 
min, the particle size decreased from 426 ± 0.25 nm to 217 ± 0.41 nm for GB-SLNs and 384 ± 
0.29 nm to 195 ± 0.37 nm for GP-SLNs respectively. However, increasing homogenisation time 
to 15 min shown no further decrease in particle size for both GB-SLN and GP-SLN formulations. 
As extended exposure of SLNs to excessive cavitation forces may lead to collision and therefore 
aggregation (Mehnert et al. 2001), SLN formulations were prepared using an optimised 
homogenisation process at 10,000 rpm for 10 min. 
 
3.2 Optimisation of formulation variables 
3.2.1 Effect of lipid and drug ratio 
SLNs were prepared using different concentrations of solid lipid with respect to drug and the 
impact of lipid concentration on mean particle size and %DEE was measured (Table 1). It was 
observed that an increase in lipid concentration with respect to drug, from 3 to 10 % w/w for both 
GB and GP lipids, caused an increase in particle size from 224.15 ± 5.28 nm to 839.58 ± 3.48 nm 
and 201.73 ± 9.23 nm to 719.31 ± 6.46 nm respectively, which may be related to the increased 
viscosity of the samples. Increase in lipid concentration from 3 to 5% (w/w), caused an increase 
in % DEE for both GB-SLNs and GP-SLNs, but a decrease in % DEE upon further increases in 
lipid concentration to 7.5 and 10 % (w/w).  
These changes in DEE may occur due to crystallisation of lipid, which results in expulsion of drug 
on surface of particles and also high lipid concentration may cause a decrease in diffusion and 
hence few lipid molecules will be carried into the aqueous phase and therefore reducing entrapment 
of drug (Abdelbary and Fahmy 2009). 
3.2.2 Effect of surfactant and cosurfactant ratio 
Formation of nanoparticles increases attractive forces between particles due to their small size, 
which increases surface tension at the interface and leads to physical instability of system. It is 
important to use an effective concentration of surfactant in the formulation to facilitate particle 
repulsion and reduce surface tension of the system, however excess surfactant should be avoided 
to minimise decreases in % DEE, burst release, toxicity and irritation effects of surfactant. T80 has 
been used previously as a non-ionic stabiliser for SLN systems (Soares et al. 2013, Shah et al. 
2015). It has been reported that a combination of surfactants is more effective for formation of 
small particles that are stable on storage on, hence TP, a known permeation enhancer, was used as 
a cosurfactant in SLN formulations (Patel et al. 2010). . 
Increasing the ratio of surfactant and cosurfactant from 1:1 to 4:1 resulted in a corresponding 
decrease in both particle size as well as %DEE of SLNs in both GB-SLNs and GP-SLNs (Table 
1). A reduction in particle size can be explained by an effective reduction in interfacial tension 
between aqueous and lipid phases leading to formation of smaller particles and formation of a 
steric barrier on the particle surface, thereby preventing coalescence (Liu et al. 2007). High 
surfactant levels in the aqueous phase might increase partitioning of drug from the internal lipid 
phase to the external phase, decreasing DEE in SLNs (Rahman et al. 2010). Based on the 
optimisation studies, lipid with concentrations of 3% and 5% w/w, along with Smix (T80: TP) of 
2:1, were selected for further study, i.e.  GB3-2 and GB5-2 for glyceryl behenate-containing 
formulations and GP3-2 and GP5-2 for glyceryl palmitostearate-containing formulations. 
 
3.3 Characterisation of optimised solid lipid nanoparticles 
3.3.1 Determination of particle size, zeta potential and percent drug entrapment efficiency 
Mean particle size of both lipid formulations ranged from 192.23 ± 6.39 nm to 231.72 ± 4.31 nm. 
SLNs produced with GB were larger than those containing GP, which may be due to differences 
in chain lengths and viscosities of lipid used. GB contains glycerol esters of behenic acid (C22), 
where the main fatty acid is behenic acid > 85% but other fatty acids (C16-C20) are also present. 
GP is composed of palmitic (C16) and stearic acid (C18) >90%. A higher viscosity and longer 
hydrocarbon chain length of GB might contribute to the larger particle size. 
All formulations had a negative ZP, varying from -20.3 ± 0.9 to -29.9 ± 2.1 mV, indicating 
relatively good stability and dispersion quality (Essa et al., 2011; Negi et al., 2014). It was also 
observed that the type of lipid used had no direct relationship with measured zeta potential values. 
%DEE ranged from 77.17 ± 0.26 to 82.19 ± 1.42. The %DEE mainly depends upon the nature of 
lipids being used as crystalline nature of lipids can lead to lattice formation causing drug expulsion 
and lipids which are amorphous complex mixtures of triglycerides form less perfect crystals with 
many imperfections offering more space to accommodate drugs (Müller, Mäder, and Gohla 2000, 
Tupal et al. 2016). Thus, size, charge and encapsulation efficiency were considered suitable for 
these to be a potential system for delivery of effective amounts of TSN topically. 
3.3.2 Differential scanning calorimetry 
DSC thermograms for TSN, GB and GP, physical mixtures of drug with both lipids (PM) and TSN 
loaded SLNs are shown in Figures 1A and B. TSN has a sharp melting endotherm at 61°C, 
indicating a degree of crystallinity. The endothermic peak of pure drug was also present in the 
physical mixture, while pure lipids showed a sharp peak at 76.8°C and 57°C for GB and GP 
respectively.  
TSN-loaded SLNs exhibited broad endothermic peaks at early temperature point around 64°C and 
45°C for GB and GP. A reduction in endothermic peak temperature of TSN as well as merging of 
two separate endothermic peaks of TSN and lipids in the SLN formulation generally represents 
the homogenous dispersion of drug in lipid and nanometric size of the particles (Westesen and 
Bunjes, 1995, Shah et al., 2015). 
3.3.3 Powder X-ray diffraction analysis 
To study the effect of different glycerides on the crystallinity of TSN in formulation, XRD analysis 
was performed for pure TSN, GB and GP and TSN-loaded SLNs. TSN is a crystalline material 
having major diffraction peaks at 2θ scattered angles 8.2, 24.4 and 25.4 respectively (Celebioglu 
et al. 2013). The XRD of GB confirms its semi crystalline nature (Figure 2A) with a sharp peak at 
2θ angles of 21.18, 23.38 while GP produces peak at 2θ angles of 19.5, 21.5 and 23.5 (Figure 
2B). The values are similar to those reported for the lipids in the literature (Bhagwat et al. 2009, 
Josea et al. 2014). However, a reduction in intensity of TSN peak for both GB-SLNs and GP-SLNs 
indicates a reduction in crystallinity of TSN, following encapsulation of the drug in the lipid 
(Jenning and Gohla 2001). Similar results were observed for lipid based nanocarriers of decitabine 
(Yub et al. 2014) and clotrimazole (Das et al. 2012) and confirm molecular dispersion of the drug 
in the lipid.  
 
3.3.4 Nanoparticle morphology 
TEM images (Figure 3A) and particle size data confirmed the spherical nature and nanosized 
dimensions of the formulations <250 nm. TEM images (Figure 3B) of SLNs showed a darker 
central area, which is likely to arise due to drug distribution through the lipid region as proposed 
following DSC and XRD analysis of formulations.  
 
3.3.5 Stability studies 
SLN formulations were stored in glass vials and placed at room temperature (20±2°C) and 
controlled humidity conditions (40°C/75% RH) to determine stability of formulation in terms of 
mean particle size, PDI and ZP of SLNs for up to 90 days. There were no statistically significant 
differences (p>0.05) in either PDI or ZP for both types of lipid formulations under the different 
storage conditions (Tables 2 and 3). 
3.3.6 Skin permeation studies 
3.3.6.1 In vitro diffusion permeation studies  
Skin permeation studies are relevant while studying topical drug delivery to ensure that 
formulations display minimum permeation through skin into the receiver medium and maximum 
skin deposition. The influence of type and concentration of lipids and surfactant used, along with 
other physicochemical parameters on TSN permeation and retention within the skin were 
evaluated using in vitro skin permeation studies. Skin permeation studies were carried out using 
excised full thickness porcine ear skin with selected TSN-loaded SLN formulations and saturated 
aqueous solution of TSN as the control (Figure 4).  
 
SLN formulations had a 4.5-fold higher rate of permeation of TSN compared to a control solution. 
Similar results were reported for GB-based fluconazole SLNs, which had a 1.73-fold higher 
fluconazole permeation compared to control solution (Gupta and Vyas, 2012). The increased 
dermal delivery of drug can be attributed to the structure and physicochemical properties of SLNs. 
It has been shown that due to their occlusive nature and increased skin hydration of SC, SLNs 
influence the percutaneous permeation of drugs present in the formulations (Gupta and Vyas, 
2012; Schäfer-Korting et al., 2007). Increasing lipid concentrations to 5% w/w  (GB5-2 and GP5-
2) resulted in a 2-fold increase in TSN permeation compared to GB3-2 and GP3-2 formulations 
respectively, which might be due to smaller particle size, higher % DEE and a more occlusive 
effect due to lipid content. In this study, the type and concentration of lipid affected the flux of 
TSN as GP5-2 formulation exhibited the highest diffusion rate through skin compared to other 
formulations and the control (p<0.002) (Table 4). 
 
3.3.6.2 Quantification of triclosan in the skin  
The amount of TSN retained within skin was determined by adhesive tape stripping and 
cyanoacrylate biopsies. A differential stripping technique was used to quantify TSN levels in 
different areas of the skin, including hair follicles, epidermis and dermis and the results are 
presented in Figure 5. SLNs significantly increased TSN retention within the skin compared to the 
control solution, (p<0.05). Epidermal targeting by SLNs was proposed to be due to occlusion and 
interaction of SLNs with skin lipids (Chen et al. 2006). GP-based SLNs delivered more TSN into 
the skin and hair follicles compared to GB-based SLNs.  
The amount of TSN recovered from skin appendages through cyanoacrylate biopsy was dependent 
on the concentration of lipid used in the formulations. As lipid concentration increased from 3% 
to 5% (w/w) in GB-based SLNs, there was a 2-fold increase in TSN concentration from 0.28 ± 
0.07 µg/mg to 0.57 ± 0.08 µg/mg while for GP-based SLNs, the concentration of TSN increased 
from 0.97 ± 0.04 µg/mg to 1.99 ± 0.14 µg/mg in the appendages. The application of the GP5-2 
SLN formulation increased TSN retention in skin and in the follicles, most likely due to their small 
size and high encapsulation efficiency. Thus, this deeper penetration of drug into skin and targeted 
delivery of follicles render it a promising formulation for effective antiseptic delivery into the skin. 
 
4. Conclusion 
This study demonstrates the potential of a lipid-based formulation to increase the dermal 
absorption of TSN. Biodegradable lipids GB and GP along with a mixture of surfactant, T80 and 
TP were used to produce stable SLNs. Various process and formulation parameters were analysed 
to optimise SLNs for skin delivery. In vitro permeation studies showed GP formulations containing 
lipid-to-drug ratio of 5:1 preferentially targeted the follicular route compared to both GB 
formulation and control solution. Using SLNs to target antiseptic agents to the skin appendages 
has potential to enhance and sustain activity to improve skin antisepsis, a major goal in the 
reduction of healthcare-associated infections. 
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Figure 1. (A) DSC thermograms of triclosan (TSN) and lipid (GB), physical mixture (PM) of GB 
and TSN, TSN loaded GB-SLNs (GB3-2, GB5-2), (B) DSC thermograms of TSN, lipid (GP), 
physical mixture (PM) of GP and TSN, TSN loaded GP-SLNs (GP3-2, GP5-2). 
Figure 2. (A) XRD powder diffractograms of triclosan (TSN), lipid (GB) andloaded nanoparticles 
(GB3-2, GB5-2), (B) XRD powder diffractograms of  triclosan (TSN) and lipid, (GP), and loaded 
nanoparticles (GP3-2, GP5-2). 
Figure 3 A and B. TEM images of triclosan loaded SLNs (1000 x). 
Figure 4. In vitro cumulative amount of triclosan permeated following 24 h topical application of 
SLN formulations and control solution through porcine ear skin (Mean ± SD, n = 6). 
Figure 5. Triclosan uptake into skin treated with SLN formulations and control solution (Mean ± 




Abdelbary, G. and Fahmy, R.H., 2009. Diazepam loaded solid lipid nanoparticles: Design and 
Characterisation. AAPS PharmSciTech, 10, 211–219. 
Aljuffali, I.A., Sung, C.T., Shen, F.M., Huang, C.T., and Fang, J.Y., 2013. Squarticles as a lipid 
nanocarrier for delivering diphencyprone and minoxidil to hair follicles and human dermal 
papilla cells. The AAPS Journal, 16 (1), 140–150. 
Bhagwat, D.A., Kawtikwar, P.S., and Sakarkar, D.M., 2009. Formulation and the in vitro and 
biopharmaceutical evaluation of sustained release tablet of verapamil HCl using Precirol 
ATO 5 through melt granulation technique. Asian Journal of Pharmaceutics, 3 (4), 278–
285. 
Carter, L., Eleanor, H., Williams, M., Ryan, J., Kookana, R., and Boxall, A., 2014. Fate and 
Uptake of Pharmaceuticals in Soil−Plant Systems. Journal of Agricultural and Food 
Chemistry, 62, 816–825. 
Celebioglu, A., Umu, O.C., Tekinay, T., and Uyar, T., 2013. Antibacterial electrospun nanofibers 
from triclosan/cyclodextrin inclusion complexes. Colloids and Surfaces B: Biointerfaces, 
116, 612–619. 
Cevc, G., 1997. Drug delivery across the skin. Expert opinion on Investigational drugs, 6, 1887–
1937. 
Chen, H., Chang, X., Du, D., Liu, W., Liu, J., Weng, T., Yang, Y., Xu, H., and Yang, X., 2006. 
Podophyllotoxin loaded solid lipid nanoparticles for epidermal targeting. Journal of 
Controlled Release, 110, 296–306. 
Das, S., Ng, W.K., and Tan, R.B.H., 2012. Are nanostructured lipid carriers (NLCs) better than 
solid lipid nanoparticles (SLNs): Development, characterisations and comparative 
evaluations of clotrimazole loaded SLNs and NLCs? European Journal of Pharmaceutical 
Sciences, 47 (1), 139–151. 
Dick, I.P. and Scott, R.C., 1992. Pig ear skin as an in vitro model for human permeability. 
Journal of Pharmaceutics and Pharmacology, 44, 640–645. 
Domínguez-Delgado, C.L., Rodríguez-Cruz, I.M., Escobar-Chávez, J.J., Calderón-Lojero, I.O., 
Quintanar-Guerrero, D., and Ganem, A., 2011. Preparation and characterisation of triclosan 
nanoparticles intended to be used for the treatment of acne. European journal of 
Pharmaceutics and Biopharmaceutics, 79 (1), 102–117. 
Essa, S., Rabanel, J.M., and Hildgen, P., 2011. Characterisation of rhodamine loaded PEG-g-
PLA nanoparticles (NPs): Effect of poly(ethyleneglycol) grafting density. International 
Journal of Pharmaceutics, 411, 178–187. 
Fagui, A., Dubot, P., Loftsson, T., and Amiel, C., 2013. Triclosan loaded with high 
encapsulation efficiency into PLA nanoparticles coated with? cyclodextrin polymer. 
Journal of Inclusion Phenomena and Macrocyclic Chemistry, 75 (3–4), 277–283. 
Flaten, G.E., Palac, Z., Engesland, A., Filipović-Grčić, J., Vanić, Ž., and Škalko-Basnet, N., 
2015. In vitro skin models as a tool in optimisation of drug formulation. European Journal 
of Pharmaceutical Sciences, 75, 10–24. 
Godin, B. and Touitou, E., 2007. Transdermal skin delivery: Predictions for human from in vivo, 
ex vivo and animal models. Advanced Drug Delivery Reviews, 59, 1152–1161. 
Grice, E.A. and Segre, J.A., 2011. The skin microbiome. Nature Reviews Microbiology, 9 (4), 
244–253. 
Gupta, M. and Vyas, S.P., 2012a. Development, characterisation and in vivo assessment of 
effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous 
candidiasis. Chemistry and Physics of Lipids, 165 (4), 454–461. 
Gupta, M. and Vyas, S.P., 2012b. Development, characterisation and in vivo assessment of 
effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous 
candidiasis. Chemistry and Physics of Lipids, 165, 454–461. 
Jenning, V. and Gohla, S., 2001. Encapsulation of retinoids in solid lipid nanoparticles. Journal 
of Microencapsulation, 18, 149–158. 
Josea, S., Anjua, S.S., Cinua, T.A., Aleykuttya, N.A., Thomasc, S., and Souto, E.B., 2014. In 
vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for 
brain delivery. International Journal of Pharmaceutics, 20 (1–2), 6–13. 
Kamble, M.S., Vaidya, K.K., Bhosale, A. V, and Chaudhari, P.D., 2012. Solid lipid 
nanoparticles and Nanostructured lipid carriers - An overview. International Journal of 
Pharmaceutical, Chemical and Biological Sciences, 2 (4), 681–691. 
Kaur, A., Goindi, S., and Katare, O., 2016. Formulation, characterisation and in vivo evaluation 
of lipid based nanocarriers for topical delivery of diflunisal. Journal of Microencapsulation, 
33 (5), 475–486. 
Khezri, K., Dizaj, M.S., and Maleki, S., 2018. Application of nanoparticles in percutaneous 
delivery of active ingredients in cosmetic preparations. Biomedicine and Pharmacotherapy, 
106, 1499–1505. 
Kim, J.C., Song, M., Kim, M., Lee, E., Park, S., Rang, M., and Ahn, H., 2002. Preparation and 
characterisation of triclosan containing vesicles. Colloids and Surfaces B: Biointerfaces, 26 
(3), 235–241. 
Kotikalapudi, L.S., Adepu, L., VijayaRatna, J., and Diwan, P. V, 2012. Formulation and in vitro 
characterisation of domperidone loaded solid lipid nanoparticles. International Journal of 
Pharmaceutical and Biomedical Research, 3 (1), 22–29. 
Kupetz, E. and Bunjes, H., 2014. Lipid nanoparticles: Drug localisation is substance specific and 
achievable load depends on the size and physical state of the particles. Journal of 
Controlled Release, 189, 54–64. 
Leaper, D., Fry, D., and Assadian, O., 2013. Perspectives in prevention and treatment of surgical 
site infection - a narrative review of the literature. Wounds, 25 (11), 313–323. 
De Lissovoy, G., Fraeman, K., Hutchins, V., Murphy, D., Song, D., and Vaughn, B.B., 2009. 
Surgical site infection: Incidence and impact on hospital utilisation and treatment costs. 
American Journal of Infection Control, 37 (5), 387–397. 
Liu, J., Gong, T., Wang, C., Zhong, Z., and Zhang, Z., 2007. Solid lipid nanoparticles loaded 
with insulin by sodium cholate phosphatidylcholine based mixed micelles: Preparation and 
characterisation. International Journal of Pharmaceutics, 340, 153–162. 
Mehnert, W., Mäder, K., and Wolfgang, M., 2001. Solid lipid nanoparticles production, 
characterisation and applications. Advanced Drug Delivery Reviews, 47 (2–3), 83–101. 
Mu, H. and Holm, R., 2018. Solid lipid nanocarriers in drug delivery: characterization and 
design. Expert Opinion on Drug Delivery, 15, 771–785. 
Müller, R.H., Mäder, K., and Gohla, S.H., 2000. Solid lipid nanoparticles for controlled drug 
delivery: A review of the state of the art. European Journal of Pharmaceutics and 
Biopharmaceutics, 50 (1), 161–177. 
Müller, R.H., Mäder, K., Gohla, S.H., Muller, R.H., and Mader, K., 2000. Solid lipid 
nanoparticles for controlled drug delivery: A review of the state of the art. European 
Journal of Pharmaceutics and Biopharmaceutics, 50 (1), 161–177. 
Negi, J.S., Chattopadhyay, P., Sharma, A.K., and Ram, V., 2014a. Development and evaluation 
of glyceryl behenate based solid lipid nanoparticles (SLNs) using hot self 
nanoemulsification (SNE) technique. Archives of Pharmacal Research, 37 (3), 361–370. 
Negi, J.S., Chattopadhyay, P., Sharma, A.K., and Ram, V., 2014b. Development and evaluation 
of glyceryl behenate based solid lipid nanoparticles (SLNs) using hot self-
nanoemulsification (SNE) technique. Archives of Pharmacal Research, 37 (3), 361–370. 
Nerella, A., Basava, R., and Devi, A., 2014. Formulation, optimisation and in vitro 
characterisation of letrozole loaded solid lipid nanoparticles. International Journal of 
Pharmaceutical Sciences and Drug Research, 6 (3), 183–188. 
Patel, D., Dasgupta, S., Dey, S., Ramani, Y.R., Ray, S., and Mazumder, B., 2012. 
Nanostructured lipid carriers (NLC) based gel for the topical delivery of aceclofenac: 
Preparation, characterisation, and in vivo evaluation. Scientia Pharmaceutica, 80 (3), 749–
764. 
Patel, M.J., Patel, N.M., Patel, R.B., and Patel, R.P., 2010. Formulation and evaluation of self 
microemulsifying drug delivery system of lovastatin. Asian Journal of Pharmaceutical 
Sciences, 5 (6), 266–275. 
Quintanar-Guerrero, D., Tamayo-Esquivel, D., Ganem-Quintanar, A., Allémann, E., and 
Doelker, E., 2005. Adaptation and optimization of the emulsification-diffusion technique to 
prepare lipidic nanospheres. European Journal of Pharmaceutical Sciences, 26 (2), 211–
218. 
Rahman, Z., Zidan, A.S., and Khan, M.A., 2010. Non destructive methods of charcaterisation of 
risperidone solid lipid nanoparticles. European Journal of Pharmaceutics and 
Biopharmaceutics, 76, 127–137. 
Rowe, R.C., Sheskey, P.J., Cook, W.G., and Fenton, M.E., 2012. Diethylene glycol monoethyl 
ether. In: Handbook of Pharmaceutical Excipients. Washington, DC, 256–258. 
Sabu, C., Rejo, C., Kotta, S., and Pramod, K., 2018. Bioinspired and biomimetic systems for 
advanced drug and gene delivery. Journal of Controlled Release, 287 (10), 142–155. 
Schäfer-Korting, M., Wolfgang, M., and Hans-Christian, K., 2007. Lipid nanoparticles for 
improved topical application of drugs for skin diseases. Advanced Drug Delivery Reviews, 
59, 427–443. 
Schäfer-Korting, M., Wolfgang, M., and Korting, H., 2007. Lipid nanoparticles for improved 
topical application of drugs for skin diseases. Advanced Drug Delivery Reviews, 59, 427–
443. 
Shah, B., Khunt, D., Bhatt, H., Misra, M., and Padh, H., 2015. Application of quality by design 
approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on 
formulation and characterisation parameters. European Journal of Pharmaceutical 
Sciences, 78, 54–66. 
Soares, S., Fonte, P., Costa, A., Andrade, J., Seabra, V., Ferreira, D., Reis, S., and Sarmento, B., 
2013. Effect of freeze drying, cryoprotectants and storage conditions on the stability of 
secondary structure of insulin-loaded solid lipid nanoparticles. International Journal of 
Pharmaceutics, 456 (2), 370–381. 
Suller, M.T. and Russell,  a D., 2000. Triclosan and antibiotic resistance in Staphylococcus 
aureus. The Journal of Antimicrobial Chemotherapy, 46, 11–18. 
Teichmann, A., Jacobi, U., Ossadnik, M., Richter, H., Koch, S., Sterry, W., and Lademann, J., 
2005. Differential stripping: Determination of the amount of topically applied substances 
penetrated into the hair follicles. Journal of Investigative Dermatology, 125, 264–269. 
Tupal, A., Sabzichi, M., Ramezani, F., Kouhsoltani, M., and Hamishehkar, H., 2016. Dermal 
delivery of doxorubicin-loaded solid lipid nanoparticles for the treatment of skin cancer. 
Journal of Microencapsulation: Micro and Nano Carriers, 33 (4), 372–380. 
Vilela, R., Jacomo, A.D.N., and Tresoldi, A.T., 2007. Risk factors for central venous catheter-
related infections in paediatric intensive care. Clinical Science, 62 (5), 537.544. 
Wosika, H. and Cal, K., 2010. Targeting to hair follicles: Current status and potential. Journal of 
Dermatological Science, 57, 83–89. 
Yub, R., Srivastava, M., Ahmad, N., Kumar, N., Bhatnagar, A., and Kohli, K., 2014. Lipid based 
nanocarrier system for the potential oral delivery of decitabine: Formulation design, 





 Table 1. Effect of concentration of lipids and surfactants on particle size and percent entrapment 
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 Table 2. Particle size, polydispersity index (PDI) and zeta potential (ZP) of SLN formulations 
stored at room temperature 20±2ºC. (Mean ± SD, n=3). 
 
Duration Formulations Particle size   (nm) PDI ZP (mV) 
Day 0 GB3-2 175.2 ± 9.2 0.86 ± 0.03 -20.3 ± 0.9 
 GB5-2 180.1 ± 7.3 0.89 ± 0.01 -25.9 ± 0.6 
 GP3-2 193.8 ± 8.3 0.62 ± 0.05 -24.4 ± 0.8 
 GP5-2 169.3 ± 6.2 0.87 ± 0.04 -29.9 ± 1.2 
     
Day 30 GB3-2 175.3 ± 10.6 0.86 ± 0.02 -25.3 ± 0.6 
 GB5-2 188.2 ± 8.4 0.61 ± 0.07 -29.1 ± 0.5 
 GP3-2 194.3 ± 9.5 0.73 ± 0.03 -29.0 ± 0.4 
 GP5-2 170.6 ± 7.3 0.89 ± 0.08 -30.3 ± 0.9 
     
Day 60 GB3-2 180.2 ± 10.9 0.92 ± 0.01 -24.6 ± 0.5 
 GB5-2 203.8 ± 9.3 0.68 ± 0.04 -26.5 ± 0.4 
 GP3-2 198.2 ± 9.8 0.83 ± 0.08 -32.7 ± 0.7 
 GP5-2 179.6 ± 8.1 0.96 ± 0.09 -29.4 ± 0.9 
     
Day 90 GB3-2 188.9 ± 11.2 0.93 ± 0.03 -28.8 ± 0.8 
 GB5-2 209.6 ± 9.7 0.72 ± 0.07 -25.5 ± 0.3 
 GP3-2 216.2 ± 10.3 0.86 ± 0.04 -22.6 ± 0.6 
 GP5-2 184.7 ± 8.6 0.98 ± 0.06 -28.7 ± 0.8 
 
GB3-2-solid lipid nanoparticles comprising glyceryl behenate 3% w/w and with a surfactant/cosurfactant ratio of 2:1 
GB5-2-solid lipid nanoparticles comprising glyceryl behenate 5% w/w and with a surfactant/cosurfactant ratio of 2:1 
GP3-2-solid lipid nanoparticles comprising glyceryl palmitostearate 3% w/w and with a surfactant/cosurfactant ratio 
of 2:1 
GP3-2-solid lipid nanoparticles comprising glyceryl palmitostearate 5% w/w and with a surfactant/cosurfactant ratio 
of 2:1 
 
Table 3. Particle size, polydispersity index (PDI) and zeta potential (ZP) of SLN formulations 





PDI ZP (mV) 
Day 0 GB3-2 175.2 ± 9.2 0.86 ± 0.03 -20.3 ± 0.9 
 GB5-2 180.1 ± 7.3 0.89 ± 0.01 -25.9 ± 0.6 
 GP3-2 193.8 ± 8.3 0.62 ± 0.05 -24.4 ± 0.8 
 GP5-2 169.3 ± 6.2 0.87 ± 0.04 -29.9 ± 1.2 
     
Day 30 GB3-2 180.3 ± 10.2 0.93 ± 0.02 -26.8 ± 1.2 
 GB5-2 195.6 ± 7.9 0.95 ± 0.04 -30.2 ± 1.5 
 GP3-2 200.3 ± 8.4 0.74 ± 0.05 -29.9 ± 1.3 
 GP5-2 168.9 ± 6.9 0.85 ± 0.03 -33.8 ± 1.8 
     
Day 60 GB3-2 208.5 ± 11.4 1.02 ± 0.08 -29.4 ± 1.6 
 GB5-2 220.6 ± 8.3 1.31 ± 0.04 -32.4 ± 1.8 
 GP3-2 203.2 ± 8.6 1.24 ± 0.03 -31.7 ± 1.9 
 GP5-2 174.8 ± 7.2 1.06 ± 0.06 -34.9 ± 2.1 
     
Day 90 GB3-2 217.4 ± 11.6 1.34 ± 0.01 -32.8 ± 1.9 
 GB5-2 228.1 ± 9.2 1.45 ± 0.04 -33.5 ± 2.3 
 GP3-2 210.5 ± 9.1 1.30 ± 0.07 -32.4 ± 2.5 
 GP5-2 209.7 ± 7.8 1.25 ± 0.05 -34.9 ± 2.7 
GB3-2-solid lipid nanoparticles comprising glyceryl behenate 3% w/w and with a surfactant/cosurfactant ratio of 2:1 
GB5-2-solid lipid nanoparticles comprising glyceryl behenate 5% w/w and with a surfactant/cosurfactant ratio of 2:1 
GP3-2-solid lipid nanoparticles comprising glyceryl palmitostearate 3% w/w and with a surfactant/cosurfactant ratio 
of 2:1 




 Table 4. In vitro permeability parameters of TSN-loaded SLN formulations and control solution 
in porcine ear skin (Mean ± SD, n = 6). 
 
 
Formulation Flux (Jss) 
µg/cm2/h 
Permeability coefficient 
(Kp) x 10-5 cm/h 
Control 0.086 ± 0.05 0.86 ± 0.13 
GB3-2 0.202 ± 0.07 2.02 ± 0.06 
GB5-2 0.245 ± 0.03 2.45 ± 0.12 
GP3-2 0.279 ± 0.04 2.79 ± 0.16 
GP5-2 0.536 ± 0.06 5.36 ± 0.38 
 
 
GB3-2-solid lipid nanoparticles comprising glyceryl behenate 3% w/w and with a surfactant/cosurfactant ratio of 2:1 
GB5-2-solid lipid nanoparticles comprising glyceryl behenate 5% w/w and with a surfactant/cosurfactant ratio of 2:1 
GP3-2-solid lipid nanoparticles comprising glyceryl palmitostearate 3% w/w and with a surfactant/cosurfactant ratio 
of 2:1 
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